"We have been working with Avance on strategic valuation projects over the last few years and are pleased with the outcomes and the collaboration in general. It has helped us with understanding the future potential of our portfolio and with the modelling of innovative financial structures that may allow us to explore more challenging areas of oncology in the future"

"It has been truly a joy working and interacting with you for the past 4-5 years. You and your team have extraordinary talent and a breadth of experience ranging from business and IP strategy to market analysis, deal finding and structuring, valuation analysis, and high level brainstorming. Your IT technologies are unrivaled anywhere for their scale and level of integration across many silos of information. There are other companies that replicate a portion of what you do, but they never offer the fully integrated package. More importantly, you find information, connection, and business intelligence that is new for me and leads to changes in our strategy and decision making. I wholeheartedly endorse you and your without any reservations and I look forward to future engagements."

"It is better to be approximately right than precisely wrong,' as Warren Buffet wisely said. RI-VAL fully embodies this wisdom by streamlining biotech asset valuation. Through guided, logical steps that focus on the variables that truly matter, one can achieve a reliable, sound valuation in just minutes—whether for a single asset or an entire portfolio. That’s why I love working with this tool and highly recommend it to any biotech team conducting asset or portfolio valuations."